Eli Lilly and Company (LLY) 70.56 $LLY
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:20AM CST
Incyte Corporation (INCY) reported a fourth-quarter 2014 loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 15 cents per share.
ALNY: 95.54 (+1.67), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), NVS: 102.20 (-0.17)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:59PM CST
Celgene Corporation (CELG) was up 1.7% after the company announced that Abraxane has received a positive recommendation from the Scottish Medicines Consortium.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), LLY: 70.56 (+0.03), CELG: 115.88 (+0.16)
Research and Markets: Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
Business Wire - Wed Feb 11, 11:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgc6fb/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College
PR Newswire - Wed Feb 11, 8:00AM CST
News Highlights
LLY: 70.56 (+0.03)
Watch for Eli Lilly to Potentially Rebound After Falling 1.07% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 4:11PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.38 to a high of $70.26. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $69.77 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.56 (+0.03)
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 1.07% Sell Off
Comtex SmarTrend(R) - Mon Feb 09, 4:10PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.38 to a high of $70.26. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $69.77 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.56 (+0.03)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
These Common Medications May Put You At a Greater Risk of Developing Dementia
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 8:12AM CST
Source: Flickr user Vince Alongi. Speaking personally, I can think of fewer diagnoses that I find more terrifying than dementia, of which Alzheimer's disease makes up about 70% of all cases. I watched my grandmother deal with dementia for the...
BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03)
Lilly to Present at Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 10:00AM CST
Eli Lilly and Company (NYSE:LLY) will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST.
LLY: 70.56 (+0.03)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 3:20PM CST
OncoMed Pharmaceuticals (OMED) initiated patient dosing in a phase II study (DENALI) on its experimental cancer treatment, demcizumab, being evaluated for the treatment of patients with first-line advanced-stage non-small cell lung cancer.
OMED: 26.06 (+0.30), LLY: 70.56 (+0.03), PRTA: 22.89 (+0.13), CELG: 115.88 (+0.16)
Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Feb 05, 10:00AM CST
How pharma ETFs are looking after the string of earnings beat and disappointing guidance?
IHE: 163.48 (+1.38), JNJ: 99.62 (+1.18), PPH: 67.69 (+0.60), PJP: 73.81 (+0.69), MRK: 58.81 (-0.07), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Canada Feed additives market - Growth, Trends And Forecasts (2014-2020)
M2 - Thu Feb 05, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfrqfd/canada_feed) has announced the addition of the "Canada Feed additives market - Growth, Trends And Forecasts (2014-2020)" report to their offering. Canada feed additives market has recorded steady growth rates owing to the increased demand for animal based products. Rise in global trade has also impelled the market for feed additives. To counter the health concerns over disease outbreaks among livestock, and for efficient management of feed and meat based products, Canada market is dependent on wide range of feed additives offered. The regulatory framework for approval of feed additives and the small size of market segments have been major obstacles in the Canadian market. With ban on antibiotics and their subsequent claims of ineffectiveness over a long period of time, the producers are now looking at better prospects for replacement and providing high quality feeds. In the Canadian markets, amino acids hold the biggest market share while Prebiotics and Probiotics show the highest growth rates. Poultry industry accounts for the maximum market share followed by Ruminant market. Lallemand Inc., Alltech Inc., ADM, Cargill Inc., Eli Lilly and Company, Novus International are some of the leading market players in the country. Why should you buy this report? 1 )For getting a comprehensive overview of the Canada Feed Additives market 2) To gain wide ranging information about the major players in this industry and the strategies adopted by them. 3) To gain an insight about the major countries/regions in which this industry is blooming and also identify the regions which are untapped. Key Topics Covered: 1. Introduction 2. Key Findings of the study 3. Market Overview 4. Market Segmentation By Type 5. By Animal Type 6. Competitive Landscape Overview - Feed Additives 7. Company Profiles 8. Appendix For more information visit http://www.researchandmarkets.com/research/hf...anada_feed
LLY: 70.56 (+0.03)
Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly and Company, GlaxoSmithKline, Otsuka Pharmaceutical and Pfizer
M2 - Thu Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6wrqpg/antidepressant) has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering. Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which in turn can result in an increase in the overall consumption of medicines. According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market. Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disorder Overview 08. Market Landscape 09. Market Segmentation by Mechanism of Action 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis - AstraZeneca - Aurobindo Pharma - Bristol-Myers Squibb - Dr. Reddy's Laboratories - Eli Lilly and Company - GlaxoSmithKline - H. Lundbeck - Janssen Pharmaceuticals - Lupin - Novartis - Otsuka Pharmaceutical - Pfizer - Pierre Fabre - Shire - SomersetPharmaceuticals - Sun Pharmaceutical - Sunovion Pharmaceuticals - Takeda Pharmaceutical - Teva Pharmaceutical - Torrent Pharmaceuticals - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/6w...depressant
ABT: 46.09 (+0.87), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Research and Markets: Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly and Company, GlaxoSmithKline, Otsuka Pharmaceutical and Pfizer
Business Wire - Wed Feb 04, 3:12PM CST
Research and Markets (http://www.researchandmarkets.com/research/5nw6vs/antidepressant) has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering.
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:20AM CST
Incyte Corporation (INCY) reported a fourth-quarter 2014 loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 15 cents per share.
ALNY: 95.54 (+1.67), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), NVS: 102.20 (-0.17)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:59PM CST
Celgene Corporation (CELG) was up 1.7% after the company announced that Abraxane has received a positive recommendation from the Scottish Medicines Consortium.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), LLY: 70.56 (+0.03), CELG: 115.88 (+0.16)
Research and Markets: Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
Business Wire - Wed Feb 11, 11:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgc6fb/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College
PR Newswire - Wed Feb 11, 8:00AM CST
News Highlights
LLY: 70.56 (+0.03)
Watch for Eli Lilly to Potentially Rebound After Falling 1.07% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 4:11PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.38 to a high of $70.26. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $69.77 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.56 (+0.03)
Look for Shares of Eli Lilly to Potentially Rebound after Yesterday's 1.07% Sell Off
Comtex SmarTrend(R) - Mon Feb 09, 4:10PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.38 to a high of $70.26. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $69.77 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.56 (+0.03)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
These Common Medications May Put You At a Greater Risk of Developing Dementia
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 8:12AM CST
Source: Flickr user Vince Alongi. Speaking personally, I can think of fewer diagnoses that I find more terrifying than dementia, of which Alzheimer's disease makes up about 70% of all cases. I watched my grandmother deal with dementia for the...
BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03)
Lilly to Present at Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 10:00AM CST
Eli Lilly and Company (NYSE:LLY) will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015. Alfonso Zulueta, Sr. Vice President and President, Emerging Markets will participate in a fireside chat at 8:25 a.m. EST.
LLY: 70.56 (+0.03)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
OncoMed Starts Dosing in Non-Small Cell Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 3:20PM CST
OncoMed Pharmaceuticals (OMED) initiated patient dosing in a phase II study (DENALI) on its experimental cancer treatment, demcizumab, being evaluated for the treatment of patients with first-line advanced-stage non-small cell lung cancer.
OMED: 26.06 (+0.30), LLY: 70.56 (+0.03), PRTA: 22.89 (+0.13), CELG: 115.88 (+0.16)
Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Feb 05, 10:00AM CST
How pharma ETFs are looking after the string of earnings beat and disappointing guidance?
IHE: 163.48 (+1.38), JNJ: 99.62 (+1.18), PPH: 67.69 (+0.60), PJP: 73.81 (+0.69), MRK: 58.81 (-0.07), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)
Canada Feed additives market - Growth, Trends And Forecasts (2014-2020)
M2 - Thu Feb 05, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfrqfd/canada_feed) has announced the addition of the "Canada Feed additives market - Growth, Trends And Forecasts (2014-2020)" report to their offering. Canada feed additives market has recorded steady growth rates owing to the increased demand for animal based products. Rise in global trade has also impelled the market for feed additives. To counter the health concerns over disease outbreaks among livestock, and for efficient management of feed and meat based products, Canada market is dependent on wide range of feed additives offered. The regulatory framework for approval of feed additives and the small size of market segments have been major obstacles in the Canadian market. With ban on antibiotics and their subsequent claims of ineffectiveness over a long period of time, the producers are now looking at better prospects for replacement and providing high quality feeds. In the Canadian markets, amino acids hold the biggest market share while Prebiotics and Probiotics show the highest growth rates. Poultry industry accounts for the maximum market share followed by Ruminant market. Lallemand Inc., Alltech Inc., ADM, Cargill Inc., Eli Lilly and Company, Novus International are some of the leading market players in the country. Why should you buy this report? 1 )For getting a comprehensive overview of the Canada Feed Additives market 2) To gain wide ranging information about the major players in this industry and the strategies adopted by them. 3) To gain an insight about the major countries/regions in which this industry is blooming and also identify the regions which are untapped. Key Topics Covered: 1. Introduction 2. Key Findings of the study 3. Market Overview 4. Market Segmentation By Type 5. By Animal Type 6. Competitive Landscape Overview - Feed Additives 7. Company Profiles 8. Appendix For more information visit http://www.researchandmarkets.com/research/hf...anada_feed
LLY: 70.56 (+0.03)
Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly and Company, GlaxoSmithKline, Otsuka Pharmaceutical and Pfizer
M2 - Thu Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6wrqpg/antidepressant) has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering. Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which in turn can result in an increase in the overall consumption of medicines. According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market. Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disorder Overview 08. Market Landscape 09. Market Segmentation by Mechanism of Action 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis - AstraZeneca - Aurobindo Pharma - Bristol-Myers Squibb - Dr. Reddy's Laboratories - Eli Lilly and Company - GlaxoSmithKline - H. Lundbeck - Janssen Pharmaceuticals - Lupin - Novartis - Otsuka Pharmaceutical - Pfizer - Pierre Fabre - Shire - SomersetPharmaceuticals - Sun Pharmaceutical - Sunovion Pharmaceuticals - Takeda Pharmaceutical - Teva Pharmaceutical - Torrent Pharmaceuticals - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/6w...depressant
ABT: 46.09 (+0.87), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Research and Markets: Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly and Company, GlaxoSmithKline, Otsuka Pharmaceutical and Pfizer
Business Wire - Wed Feb 04, 3:12PM CST
Research and Markets (http://www.researchandmarkets.com/research/5nw6vs/antidepressant) has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering.
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
